Tuesday, June 10, 2014 11:33:46 AM
The next pop would likely need either huge progress announcements or anticipation/announcement of an acquisition.
as for this being way overvalued based on revenue flow, anybody who has been involved in clinical trials knows just how expensive these sorts of things are. achn does not have anything on the market so are still going off the $200M infusino they got last year. they expect it to get them to significant milestones in development of their current drugs. they're not desperate for funding at the moment, but they're only a couple of years away from that point. either someone picks them up, or they have no problem getting additional funding by issuing another $5M shares at $10 each for another $50M in capital with minimal dilution... they're not in a bad position if you look at the potential revenue based on what Gilead has done and what similar pipelines are being acquired for.
Biotech is rarely rational when it moves big up or down. But it is fun!
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM